Iktos

Iktos is a French technology company that develops specialized AI software for the design of novel drug candidates within pharmaceutical research. The platform utilizes generative deep learning models to accelerate the discovery of molecules with specific biological properties. By automating complex design cycles, the tool enables researchers to significantly reduce the time and costs associated with the preclinical development phase.

The technological foundation is a proprietary platform specializing in generative chemistry, capable of efficiently optimizing molecular structures. Users can integrate existing chemical libraries or have the system generate new, optimized molecular structures that meet specific pharmacological requirements. The software serves as an intelligent assistant for chemists to improve the success rate in selecting potential drug candidates.

Beyond software solutions, Iktos offers strategic collaborations for the pharmaceutical industry, tailoring AI models to address specific research questions. The focus remains on precisely controlling chemical parameters to ensure the synthetic accessibility and efficacy of new compounds during the digital design phase. The services are provided exclusively to life sciences organizations and research institutes.

• Generative Drug Design — Deployment of deep learning algorithms to automatically generate new chemical structures. The system integrates complex target requirements for pharmacological properties.
• Molecular Optimization — Systematic adjustment of existing chemical compounds to improve affinity, selectivity, or physicochemical profiles using predictive computational models.
• Synthesizability Assessment — Automated evaluation of the synthetic accessibility of proposed molecules within the platform. This reduces the risk of designs that are impractical to produce in the laboratory.

The tool is primarily intended for experts in pharmaceutical research, medicinal chemists, and biotech industry professionals. Use requires extensive expertise in chemistry and drug discovery.

A pharmaceutical company uses Iktos to accelerate the identification of new inhibitors for a specific protein target. Instead of manual screening, the AI generates thousands of optimized designs that are pre-screened for binding affinity. Researchers then select the most promising candidates for subsequent laboratory synthesis. This workflow significantly reduces the time from initial screening to physical prototype creation.

• The tool is primarily intended for experts in pharmaceutical research, medicinal chemists, and biotech industry professionals. Use requires extensive expertise in chemistry and drug discovery.
• A pharmaceutical company uses Iktos to accelerate the identification of new inhibitors for a specific protein target.
• Generative Drug Design: Deployment of deep learning algorithms to automatically generate new chemical structures. The system integrates complex target requirements for pharmacological properties.
• Molecular Optimization: Systematic adjustment of existing chemical compounds to improve affinity, selectivity, or physicochemical profiles using predictive computational models.
• Synthesizability Assessment: Automated evaluation of the synthetic accessibility of proposed molecules within the platform. This reduces the risk of designs that are impractical to produce in the laboratory.

Not suitable for users without a pharmaceutical background or for general chemical research outside of drug discovery. It is not intended as a general tool for casual chemical analysis.

• SYNTHIA (Merck KGaA) — Paid · HQ: Darmstadt, Germany · Unclear